niacinamide has been researched along with Neurofibromatosis 1 in 3 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Neurofibromatosis 1: An autosomal dominant inherited disorder (with a high frequency of spontaneous mutations) that features developmental changes in the nervous system, muscles, bones, and skin, most notably in tissue derived from the embryonic NEURAL CREST. Multiple hyperpigmented skin lesions and subcutaneous tumors are the hallmark of this disease. Peripheral and central nervous system neoplasms occur frequently, especially OPTIC NERVE GLIOMA and NEUROFIBROSARCOMA. NF1 is caused by mutations which inactivate the NF1 gene (GENES, NEUROFIBROMATOSIS 1) on chromosome 17q. The incidence of learning disabilities is also elevated in this condition. (From Adams et al., Principles of Neurology, 6th ed, pp1014-18) There is overlap of clinical features with NOONAN SYNDROME in a syndrome called neurofibromatosis-Noonan syndrome. Both the PTPN11 and NF1 gene products are involved in the SIGNAL TRANSDUCTION pathway of Ras (RAS PROTEINS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib was administered orally twice daily for consecutive 28-day cycles." | 2.78 | Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. ( Balis, FM; Choyke, PL; Dombi, E; Fox, E; Jayaprakash, N; Kim, A; Korf, B; Martin, S; Muradyan, N; Reddy, A; Tepas, K; Turkbey, B; Widemann, BC; Wolters, P, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tamura, Y | 1 |
| Ono, T | 1 |
| Sano, M | 1 |
| Fukuda, K | 1 |
| Kataoka, M | 1 |
| Satoh, T | 1 |
| Kim, A | 1 |
| Dombi, E | 1 |
| Tepas, K | 1 |
| Fox, E | 1 |
| Martin, S | 1 |
| Wolters, P | 1 |
| Balis, FM | 1 |
| Jayaprakash, N | 1 |
| Turkbey, B | 1 |
| Muradyan, N | 1 |
| Choyke, PL | 1 |
| Reddy, A | 1 |
| Korf, B | 1 |
| Widemann, BC | 1 |
| Maruyama, E | 1 |
| Takashima, S | 1 |
| Arima, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)[NCT03231306] | Phase 2 | 40 participants (Anticipated) | Interventional | 2017-11-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for niacinamide and Neurofibromatosis 1
| Article | Year |
|---|---|
Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Male; Maximum Tolerated | 2013 |
2 other studies available for niacinamide and Neurofibromatosis 1
| Article | Year |
|---|---|
Favorable effect of sorafenib in a patient with neurofibromatosis-associated pulmonary hypertension.
Topics: Adult; Benzenesulfonates; Cardiac Catheterization; Exercise Test; Female; Humans; Hypertension, Pulm | 2012 |
Nicotinamide-induced activity of alkaline phosphodiesterase I toward tumor-derived cultured cells from neurofibromatosis patients.
Topics: Enzyme Induction; Humans; Neurofibromatosis 1; Niacinamide; Phosphodiesterase I; Phosphoric Diester | 1992 |